Clinical TrialsViaskin Peanut's efficacy and safety continue to improve over time in 1-3 year olds, with new analysis supporting its proposed labeling approach.
Market OpportunityGiven the regulatory clarity, investors now have the goal line for Viaskin Peanut in sight, which is relatively derisked, and can start evaluating the commercial opportunity which could be ~$2B+ annually.
Regulatory ApprovalsThe FDA confirms requirements for Viaskin Peanut’s accelerated approval pathway in toddlers with DBV Technologies targeting BLA submissions in toddlers and children.